Pastor-Anglada M[au] - Search Results

Year	Number of Results
1986	6
1987	7
1988	4
1989	5
1990	3
1991	5
1992	2
1993	6
1994	5
1995	5
1996	6
1997	4
1998	5
1999	1
2000	4
2001	6
2002	4
2003	6
2004	10
2005	8
2006	9
2007	8
2008	11
2009	8
2010	9
2011	6
2012	12
2013	4
2014	5
2015	7
2016	10
2017	3
2018	5
2019	4
2020	3
2021	1
2022	0

1

Who Is Who in Adenosine Transport.

Pastor-Anglada M, Pérez-Torras S. Pastor-Anglada M, et al. Front Pharmacol. 2018 Jun 14;9:627. doi: 10.3389/fphar.2018.00627. eCollection 2018. Front Pharmacol. 2018. PMID: 29962948 Free PMC article. Review.

2

Nucleoside transporter proteins.

Molina-Arcas M, Casado FJ, Pastor-Anglada M. Molina-Arcas M, et al. Among authors: pastor anglada m. Curr Vasc Pharmacol. 2009 Oct;7(4):426-34. doi: 10.2174/157016109789043892. Curr Vasc Pharmacol. 2009. PMID: 19485885 Review.

3

Intestinal Nucleoside Transporters: Function, Expression, and Regulation.

Pastor-Anglada M, Urtasun N, Pérez-Torras S. Pastor-Anglada M, et al. Compr Physiol. 2018 Jun 18;8(3):1003-1017. doi: 10.1002/cphy.c170039. Compr Physiol. 2018. PMID: 29978890 Review.

4

Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies.

Pastor-Anglada M, Felipe A, Casado FJ. Pastor-Anglada M, et al. Trends Pharmacol Sci. 1998 Oct;19(10):424-30. doi: 10.1016/s0165-6147(98)01253-x. Trends Pharmacol Sci. 1998. PMID: 9803833 Review.

5

Drug uptake transporters in antiretroviral therapy.

Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J. Minuesa G, et al. Among authors: pastor anglada m. Pharmacol Ther. 2011 Dec;132(3):268-79. doi: 10.1016/j.pharmthera.2011.06.007. Epub 2011 Jul 23. Pharmacol Ther. 2011. PMID: 21816170 Review.

6

Oligomerization of equilibrative nucleoside transporters: a novel regulatory and functional mechanism involving PKC and PP1.

Grañe-Boladeras N, Williams D, Tarmakova Z, Stevanovic K, Villani LA, Mehrabi P, Siu KWM, Pastor-Anglada M, Coe IR. Grañe-Boladeras N, et al. Among authors: pastor anglada m. FASEB J. 2019 Mar;33(3):3841-3850. doi: 10.1096/fj.201800440RR. Epub 2018 Dec 6. FASEB J. 2019. PMID: 30521377

7

Inhibitor selectivity of CNTs and ENTs.

Vaskó B, Juhász V, Tóth B, Kurunczi A, Fekete Z, Krisjanis Zolnerciks J, Kis E, Magnan R, Bidon-Chanal Badia A, Pastor-Anglada M, Hazai E, Bikadi Z, Fülöp F, Krajcsi P. Vaskó B, et al. Among authors: pastor anglada m. Xenobiotica. 2019 Jul;49(7):840-851. doi: 10.1080/00498254.2018.1501832. Epub 2018 Sep 12. Xenobiotica. 2019. PMID: 30022699

8

Emerging Roles of Nucleoside Transporters.

Pastor-Anglada M, Pérez-Torras S. Pastor-Anglada M, et al. Front Pharmacol. 2018 Jun 6;9:606. doi: 10.3389/fphar.2018.00606. eCollection 2018. Front Pharmacol. 2018. PMID: 29928232 Free PMC article.

9

Drug transporter pharmacogenetics in nucleoside-based therapies.

Errasti-Murugarren E, Pastor-Anglada M. Errasti-Murugarren E, et al. Among authors: pastor anglada m. Pharmacogenomics. 2010 Jun;11(6):809-41. doi: 10.2217/pgs.10.70. Pharmacogenomics. 2010. PMID: 20504255 Review.

10

OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1.

Boces-Pascual C, Mata-Ventosa A, Martín-Satué M, Boix L, Gironella M, Pastor-Anglada M, Pérez-Torras S. Boces-Pascual C, et al. Among authors: pastor anglada m. Cell Mol Life Sci. 2021 Dec;78(23):7505-7518. doi: 10.1007/s00018-021-03959-8. Epub 2021 Oct 13. Cell Mol Life Sci. 2021. PMID: 34647142 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results